Individualized Neuromodulation for the Core Clinical Features of Drug Addiction
NCT: NCT06165198 · COMPLETED
Brief Summary
Using specific EEG biomarkers in methamphetamine-dependent individuals, this study systematically probes closed-loop tACS based on brain states, assessing dosage, neurologic and behavioral effects, while comparing its efficacy with traditional open-loop tACS methods.
Frequently Asked Questions
What is Individualized Neuromodulation for the Core Clinical Features of Drug Addiction?
Individualized Neuromodulation for the Core Clinical Features of Drug Addiction is a clinical trial registered under NCT06165198. Current status: COMPLETED.
What is the status of NCT06165198?
The current status of NCT06165198 (Individualized Neuromodulation for the Core Clinical Features of Drug Addiction) is: COMPLETED.
When did Individualized Neuromodulation for the Core Clinical Features of Drug Addiction start?
Individualized Neuromodulation for the Core Clinical Features of Drug Addiction started on 2023-09-25.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.